Curzion Pharmaceuticals Acquired by Horizon Therapeutics

Using technologies common to the semiconductor industry, a team of
investigators at the University of North Carolina at Chapel Hill and
Liquidia Technologies has created a polymer nanoparticle that can
encapsulate large loads of therapeutic molecules that may have use in
treating prostate cancer. The research, led by Joseph DeSimone,
co-principal investigator of the Carolina Center for Cancer
Nanotechnology, was published in the journal Nano Letters.